Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 12/20 | 0.88 |
| ▸ | HSD11B1 | P28845 | 16/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116774 | 1.00 | CYP2C19 (0.88) | CYP2C19HSD11B1CYP2C9CYP3A4 | |
| SCHEMBL117100 | 0.94 | CYP2C19 (1.00) | CYP2C19HSD11B1CYP2C9CYP3A4 | |
| SCHEMBL117101 | 0.94 | CYP2C19 (1.00) | CYP2C19HSD11B1CYP2C9CYP3A4 | |
| SCHEMBL10307897 | 0.93 | CYP2C19 (0.92) | CYP2C19HSD11B1CYP2C9CYP3A4 | |
| SCHEMBL4073031 | 0.91 | HSD11B1 (0.91) | CYP2C19HSD11B1CYP2C9CYP3A4 | |
| SCHEMBL589809 | 0.91 | HSD11B1 (1.00) | CYP2C19HSD11B1CYP2C9CYP3A4 | |
| SCHEMBL589810 | 0.91 | HSD11B1 (1.00) | CYP2C19HSD11B1CYP2C9CYP3A4 | |
| SCHEMBL15241493 | 0.91 | HSD11B1 (1.00) | CYP2C19HSD11B1CYP2C9CYP3A4 | |
| SCHEMBL115253 | 0.91 | HSD11B1 (1.00) | CYP2C19HSD11B1CYP2C9CYP3A4 | |
| SCHEMBL115252 | 0.91 | HSD11B1 (1.00) | CYP2C19HSD11B1CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424865-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2017-01-18 | — | — | EP | disclosed |
| EP-2687525-B1 | CYCLIC INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-8754076-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | Vitae Pharmaceuticals, Inc./Boehringer-Ingelheim (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8680093-B2 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2687525-A1 | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | Boehringer Ingelheim International GmbH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8629138-B2 | — | — | 2014-01-14 | — | — | US | disclosed |
| US-8575157-B2 | — | — | 2013-11-05 | — | — | US | disclosed |
| EP-2324018-B1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-04 | — | — | EP | disclosed |
| US-20130096108-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2013-04-18 | — | — | US | disclosed |
| EP-2300461-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2424865-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Boehringer Ingelheim International GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-8114868-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-02-14 | — | — | US | disclosed |
| EP-2324018-A1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2300461-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20110021512-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-01-27 | — | — | US | disclosed |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2011-01-13 | — | — | US | disclosed |
| US-20100331320-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010127237-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010011314-A1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009134400-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096108-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD17B1 | CYP2C19 91/4885HSD11B1 1/4885CYP2C9 108/4885 |
| US-20110021512-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD3B1 | CYP2C19 462/4885HSD11B1 1/4885CYP2C9 435/4885 |
| US-20110009402-A1 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD11B2, HSD3B1 | CYP2C19 248/4885HSD11B1 1/4885CYP2C9 315/4885 |
| US-20100331320-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | CYP2C19 246/4885HSD11B1 1/4885CYP2C9 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.